Researchers at MIT have developed a mathematical model that can calculate whether diabetes treatments in pre-clinical trials will be successful in humans.
List view / Grid view
Filter the results
A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
In light of the COVID-19 pandemic, the creators of the Clinical Research Navigator (CRN) tool have offered free access to their system for biomedical researchers.
To reach the full potential of artificial intelligence (AI) in the pharma industry, it is essential that companies harmonise their data to remove the need for unnecessary human intervention. This article outlines how companies are working towards digital maturation and the obstacles they need to overcome to ensure the value…
Advances in informatics have afforded researchers the ability to extrapolate petabytes of human genomics data and translate it into biologically relevant information. However, further translating this information into knowledge can prove challenging. Slavé Petrovski, Vice President and Head of Genome Analytics and Bioinformatics for AstraZeneca’s Centre for Genomics Research, spoke…
Gone are the days where mere data is considered king. We now understand the real value is in proper data management; but how best to harness its value? This article addresses current market options for companies wanting to extract every ounce of knowledge from raw data.
Researchers are working to build a complete, all-atom model of the exterior of the coronavirus to aid in drug design.
The novel technology allows researchers to create three-dimensional images of signal propagation and calcium concentration changes in the neocortex of live mice.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
A new technology called mass cytometry, or CyTOF, is providing new insights into a range of key proteins in blood cancer cells.
Using AI and deep learning, researchers have enhanced Scanning Probe Microscopy (SPM) and made their automated resource available for scientists.
Drug Target Review explores the findings of a recent review of molecular, cellular, multi-cellular and tissue engineering and modelling technologies for drug design.
New in silico screening software has the capability to screen billions of compounds, with the hope of improving drug design and limiting side effects.